Channel - Genitourinary (prostate included)
5/31/2022 11:48:17 PM

Channel Videos

79.8Gy Image Guide Radiotherapy for Prostate Cancer: The Princess Margaret Experience
Jarad Martin
10/23/2009 11:04:00 PM

Algorithm for Correction of Catheter Displacement in High Dose Rate (HDR) Prostate Brachytherapy - a Simulation Study
Dr. Wee Loon Ong
10/30/2015 10:00:00 PM

Are fiducial markers still the gold standard for prostate image guided radiation therapy (IGRT)?
Dr Thomas Eade
10/18/2013 10:20:00 PM

Beware Changing FSDs and VMAT in Prostate Cancer
Katherine Stanley
7/28/2012 1:50:00 AM

Bone and Joint Infections.
Susanne Guy
10/16/2010 1:00:00 AM

Changing Paradigms in Chemotherapy & ADT - Updates on Recent Prostate Cancer Trials
Prof Gavin Marx
10/31/2015 5:00:00 AM

Contouring Workshop - Genitourinary
Dr. Michael Milosevic MD, FRCPC
10/17/2008 11:00:00 AM

Contrast-enhanced US of Renal Lesions: Bubbling Along
Dr Alain Lavoipierre
10/7/2011 3:55:00 AM

Development and Evaluation of an Automated System to Detect Clinical Stage Data from the Electronic Record in Patients with Genitourinary Cancers
Dr Richard Khor
10/29/2015 1:00:00 AM

Effect of hydrogel and hyaluronic acid rectal spacer on rectal dosimetry and toxicity in low-dose-rate prostate brachytherapy
Dr Yuan-Hong Lin
9/17/2021 11:25:00 PM

Evaluation of set-up accuracy of the inguinal regions using cone-beam CT in anal cancer patients treated with IMRT
Dr Meredith Johnston
10/19/2013 10:20:00 PM

FRO Genitourinary Group AGM
10/17/2013 6:15:00 AM

FROGG # 2 Genitourinary Sessions for Radiation Oncology Trainees, supported by Mundipharma (Eligard)
Topic: Radiotherapy for Prostate, Pelvic nodes and Oligo metastasis from Prostate RANZCR is excited to announce the second session in our FROGG Webinar Series, in partnership with Mundipharma (Eligard). Registration is free for RANZCR trainees. The second session will be with Prof Andrew Loblaw and A/Prof Patrick Cheung from Sunnybrook Health Sciences Centre, Toronto, Canada. This session will be slightly different in format; Prof Loblaw will chair the session, which will be conducted like an interview discussion between himself and A/Prof Cheung. Speakers: A/Prof Patrick Cheung
Prof Andrew Loblaw
11/13/2020 7:00:00 AM

FROGG # 3 Genitourinary Sessions for Radiation Oncology Trainees, supported by Mundipharma (Eligard)
During the third session, our guest speaker will be Dr Alison Tree, Consultant Clinical Oncologist, The Royal Marsden Hospital. Radiotherapy technology has undergone a revolution over the last decade, with fractionation, dosimetry and image-guidance changing almost beyond recognition. This has enabled us to deliver bold new treatments, develop whole new machines like the MR Linac, and expand the reach of radiotherapy into metastatic disease. But radiotherapy technology is expensive and healthcare budgets are not infinite. Are radiotherapy innovations been driven by evidence and clinical need, or are these innovations driven by what is possible, rather than sensible? Come and join the discussion! Speakers: Dr Alison Tree
Default Presenter
3/15/2021 7:00:00 AM

FROGG #4 Genitourinary Sessions for Radiation Oncology Trainees, supported by Mundipharma (Eligard)
Topic: “A PoP RT and a Peep”: Creating evidence from challenges in Uro Radiation Oncology During the fourth session, our guest speaker will be Professor Vedang Murthy, Advanced Center for Treatment Research and Education in Cancer / Tata Memorial Center, Mumbai, India. Dr Murthy will discuss the recent PoP RT trial on the role of pelvic radiotherapy in high risk prostate cancer. In addition, he will highlight the peculiar challenges of SBRT in high risk and locally advanced prostate cancer. The lecture will also include technological advances in bladder and penile preservation and the evolving role of adjuvant RT in bladder and penile cancers. Professor Vedang Murthy Vedang Murthy, MD, DNB, DipEPP, is a Professor of Radiation Oncology at Tata Memorial Hospital, Mumbai. Dr Murthy's area of expertise is in Urological Cancer. Dr. Murthy did his training in the field of Radiation Oncology from Tata Memorial Hospital in 2002 before going to the United Kingdom where he worked at The Royal Marsden NHS Foundation Hospital, London for a period of 4 years in the Academic Radiotherapy Unit. He also undertook a Diploma in Epidemiology and Biostatistics from the London School of Health and Tropical Medicine. He has over 120 publications in peer reviewed international journals.  Dr Murthy is currently running several investigator initiated clinical trials including randomised controlled trials in prostate and bladder cancer and is a part of international co-operative groups in GU Oncology. The main areas of interest within GU oncology are high risk prostate cancer, SBRT for prostate and kidney cancer, oligometastatic prostate cancer, bladder preservation and adjuvant radiotherapy in bladder cancer
Prof. Vedang Murthy
6/10/2021 8:00:00 AM

FROGG #6 Genitourinary Sessions for Radiation Oncology Trainees, Supported by Mundipharma (Eligard)
Topic: Systemic Management of Prostate Cancer – Current agents and horizon scanning Learning outcomes/objectives: Defining current treatment of metastatic hormone-sensitive prostate cancer including recent clinical trials. Outlining current management of metastatic castration-resistant prostate cancer. Discussing future directions in systemic treatment of metastatic prostate cancer. Guest speakers: -  Dr Louise Kostos MBBS (Hons), FRACP. Consultant Medical. Oncologist and PhD student. Peter MacCallum Cancer Centre. Louise is a Medical Oncologist at the Peter MacCallum Cancer Centre in the genitourinary team. She has a particular interest in prostate cancer and early-phase clinical trials. Currently, Louise is currently undertaking a PhD in advancing outcomes for men with castration resistant prostate cancer who receive radionuclide therapy. - A/Prof Arun Azad MBBS PhD FRACP Associate Professor Arun Azad is an internationally recognised medical oncologist and translational researcher in urological cancers, with a particular focus on prostate cancer.
Default Presenter
11/22/2021 8:00:00 AM

FROGG #7 - Genitourinary Sessions for Radiation Oncology Trainees, Supported by Mundipharma (Eligard)
Topic: The contemporary non-surgical management of muscle-invasive bladder cancer | a case-based discussion Bladder cancer patients are subject to health inequalities and limited access to suitable treatment options in different healthcare systems. It is important that all appropriate treatment options are made available. With the growing acceptance that surgery and radiation therapy provide equivalent outcomes for patients with organ-confined muscle-invasive bladder cancer, it is important to understand the role of chemotherapy, radiation therapy and radio sensitisation. International guidelines now advise discussion of both options with suitable patients with many patients opting for bladder preservation. Radiation therapy also plays an important role in patients unsuitable for radical treatment. Webinar attendees will be able to: 1. Select patients suitable for bladder preservation 2. Discuss the merits of different radiosensitisers 3. Understand the role of hypofractionation in the treatment of bladder cancer Meet our International guest speaker: Professor Ananya Choudhury is Chair and Honorary Consultant in Clinical Oncology. She joined The Christie in 2008 specialising in urology and sarcoma and has a strong interest in translational research. In 2013, she decided to focus on radiotherapy-related research in prostate and bladder cancers. Within the Division of Cancer Sciences, The University of Manchester, she is clinical lead for advanced radiotherapy, including the MRLinac project, and is co-Group Leader of The Translational Radiobiology Group. Over the past few years, Professor Choudhury has been involved with national concerns such as the Royal College of Radiologists, the National Cancer Research Institute (NCRI) Clinical and Translational Radiotherapy Research Working Group (CTRad), the NCRI Bladder Clinical Studies Group and the National Institute of Health and Care Excellence (NICE). Since early 2021, she has been the Editor in Chief of Clinical Oncology.
3/10/2022 8:00:00 AM

FROGG Genitourinary Sessions for Radiation Oncology Trainees, supported by Mundipharma (Eligard)
3/21/2021 10:00:00 PM

Genitourinary Toxicity in Post-Prostatectomy Fossa Radiotherapy: Does Timing Heal All Wounds?
Dr Mohamed Ehsan bin Ebrahim
9/17/2021 1:40:00 AM

Genitourinary/Gastrointestinal: Questions
9/17/2021 11:40:00 PM

High dose prostate cancer radiotherapy: Late toxicity outcomes
Dr Thomas Eade
10/17/2013 4:40:00 AM

Imaging & erectile dysfunction
Professor Bill Lees
10/4/2007 8:30:00 PM

Imaging in the management of cervix cancer - the good, the bad and the ugly
Dr Karen Lim
10/19/2013 9:50:00 PM

Improved Rectal Dosimetry with the Use of Rectal Immobilisation in Stereotactic Prostate Radiotherapy
Dr Jeremiah de Leon
10/29/2015 1:15:00 AM

Improved treatment accuracy of prostate bed radiotherapy using pre treatment ultrasound
A/Prof Annette Haworth
10/19/2013 10:10:00 PM

IMR imaging of genitourinary emergencies
Dr John Spencer, Consultant Radiologist, St James’s Institute of Oncology, Leeds, UK
10/19/2013 8:30:00 PM

IMRT + IGRT in Management of Urological Cancers - A Clinician's Perspective.
Vincent Khoo
10/15/2010 2:30:00 AM

Live Webcast: Wednesday 18/03, 1:30 PM (AEDT), Breast Cancer and Genitourinary Cancer
If the webcast stops at any time please try refreshing your browser. For technical support email To post a question to the speaker, click on the speech bubble icon in the bottom right corner. Please include your name and email address. Agenda: 1:30 PM Breast Cancer Research Portfolio 3:15 PM Genitourinary Cancer Research Portfolio
3/18/2020 2:30:00 AM

Liver Imaging 2 & Radiology Scientific Proffered Papers (Specialty: Gastrointestinal / Genitourinary)
- Ultrasound of diffuse liver disease and portal hypertension (R.N. Gibson) - Comparison Between Gadolinium-BOPTA (Multihance) and a Standard Gadolinium Chelate (Magnevist) in the MRI Assessment of Potential Live Hepatic Donors (A. Holden; S. Merrilees; C. Kennedy; J. McCall) - Recurrent hepatocellular carcinoma: do enhancement features on contrast-enhanced ultrasound resemble HCC in a cirrhotic liver or metastases? (Y. Ong; H.J. Jang; T.K. Kim; P.N. Burns; S.R. Wilson) - The Impact of Hepatobiliary Phase (HBP) Scanning with Gadolinium-BOPTA (Multihance) in Focal Nodular Hyperplasia (FNH) Detection and Characterisation (A. Holden; P. Dukes; C. Kennedy; J. McCall; E. Gane)
Session Chairs: Dr James Anderson & Dr Samantha Ellis
10/5/2007 1:00:00 PM

Long-term erectile function (EF) and factors influencing EF preservation in men treated with permanent seed brachytherapy for localized prostate cancer
Dr Ben Hindson
10/17/2013 4:30:00 AM

MR imaging of genitourinary emergencies
John Spencer
10/22/2009 12:30:00 AM

Nomogram Use to Adapt Prostate Radiotherapy Target Volumes: A Prospective Study
Dr Raymond Wu
10/30/2015 1:40:00 AM

Obtaining the best outcomes for localised prostate cancer: Do the eviQ protocols deliver?
Dr Shea Wilcox
10/18/2013 1:30:00 AM

Panel Discussion: Integration and Timing of Local Therapy, ADT & Systemic Therapy in Recurrent & Metastatic Prostate Cancer
Panel speakers
10/31/2015 5:35:00 AM

Planning MRI in post-prostatectomy radiotherapy: Are we aiming too high?
Dr James Jackson
10/17/2013 4:20:00 AM

Post-Prostatectomy Dose Escalation Utilising VMAT - An Analysis of Dosimetry, Acute Toxicity and Workflow
Kenton Thompson
7/28/2012 2:10:00 AM

Practical Prostate MRI
Dr Michael Chew
5/4/2012 11:12:00 PM

Prostate cancer- high dose, low dose or no dose
Prof Anthony Zietman, Shipley Professor of Radiation Oncology, Harvard Medical School
10/17/2013 3:30:00 AM

Prostate MRI
Assoc Prof Stefan Heinze, Consultant Radiologist Royal Melbourne Hospital
5/26/2011 9:30:00 AM

Prostate MRI in the UK- NICE Guidelines Update 2014-HD
7/5/2015 2:46:05 PM

SBRT for Prostate Cancer: Role, Rationale, Results
Prof Michael Steinberg
10/31/2015 3:45:00 AM

Serum procollagen 1 amino-terminal propeptide (P1NP) in prostate cancer: pitfalls of its use as an early surrogate marker for bone metastasis
Dr Eka Moseshvili
10/19/2013 10:50:00 PM

Simultaneous Integrated Boost for Patients with High-Risk Prostate Cancer: Early Results of a Streamlined Technique.
Benjamin Chua
10/14/2010 8:10:00 AM

Superior Target Volume and Organ Stability with the Use of Endorectal Balloons in Post Prostatectomy Radiotherapy: The First Reported Australian Study
Jeremiah de Leon
7/27/2012 12:50:00 AM

Surveillance: The preferred management option for Stage I Seminoma
Dr Swetha Sridharan
10/19/2013 10:40:00 PM

The diagnostic performance of 18F-PSMA-1007 PET/CT in prostate cancer: a systematic literature review
Dr Shanalie Dias
9/18/2021 12:40:00 AM

TROG - Reflections and sculpting the future
Associate Professor Boon Chua
10/6/2007 3:00:00 PM

Urinary Issues after Prostate Cancer Treatment Webinar - Proudly Sponsored by AstraZeneca
Topic: "Management of post- treatment urinary function disturbance in prostate cancer patients". 1. Post-surgical urinary symptoms, when is the best time for salvage radiation from a functional point of view. 2. When to think of more than drug therapy - slings, artificial sphincter etc 3. Drugs to use 4. Post Radiotherapy (HDR, LDR, EBRT) urinary symptoms and how to manage them. Speakers: Dr Renu Eapen
Default Presenter
11/26/2020 7:00:00 AM

Utility of Dual Energy CT with iodinated oral contrast in the classification and localisation of acute bowel obstruction
Dr John Keller
10/18/2019 2:30:00 AM

Volumetric modulated arc therapy (VMAT) to the pelvic lymph nodes in prostate cancer - the first Australian experience
Dr Gina Hesselberg
10/17/2013 4:50:00 AM

Mediasite Showcase
Mediasite's the trusted cornerstone of any campus or enterprise video strategy. Our unyielding commitment to all things video helps you transform education, training, communications and online events.
Webcasting Video Content Management Video Delivery Integration Services Mediasite Community
Powered By Mediasite - Enterprise Video Platform
Sonic Foundry